ALEXANDRIA, Va.--(BUSINESS WIRE)--Today, the National Community Pharmacists Association released a first-of-its-kind analysis, Unpacking the Financial Impacts of Medicare Drug Price Negotiation, ...

President Donald Trump’s approach to lowering drug prices has leaned heavily on executive orders and voluntary deals with drugmakers, rather than legislation. (Andrew Harnik / Getty Images) As ...

As the Trump administration begins to make its mark on the Medicare drug price negotiation program and pursue its own policies on prescription drugs, litigation over program continues. In the two ...

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did not receive support from any Republican senators. In 2025, ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second round of negotiations as part of the Medicare Drug Price Negotiation Program ...

Hello and welcome to Health Affairs This Week. I'm your host, Jeff Byers. We are recording on 11/04/2025. In late September, CMS published its final guidance for the third cycle of the Medicare drug ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. WASHINGTON — The Trump administration is ...

The Trump administration signaled Medicare drug price negotiations under the Inflation Reduction Act (IRA) signed in 2022 by former President Joe Biden may undergo a reexamination to add greater ...

Many independent pharmacists may decide or have already decided not to carry drugs in the Medicare Drug Price Negotiation Program due to financial challenges, the National Community Pharmacists ...

“While we support affordable health care, the price controls that we are challenging would reduce access to new medicines that Americans are counting on, and would set a devastating precedent for all ...

AbbVie filed a lawsuit Feb. 11 challenging the federal government’s decision to include Botox in Medicare’s drug price negotiation program. In the complaint filed in the U.S. District Court for the ...

Please provide your email address to receive an email when new articles are posted on . Prior authorization reforms, increased biosimilar access and the future of the Medicare drug price negotiation ...